MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jiac.2026.102937

Медицинская библиотека · Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2026

Pharmacokinetic interaction between nirmatrelvir/ritonavir and nifedipine: A case report.

Takase Tomoki, Kuroda Hirokazu, Fukushima Keizo, Oda Toshihiko, Masumoto Saki, Nadai Takanobu, Hotta Takumi, Fukushima Shoji, Kume Manabu, Hashida Tohru, Muroi Nobuyuki

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

Nirmatrelvir/ritonavir (NMV-r), which is used to treat coronavirus disease 2019 (COVID-19), contains ritonavir as a pharmacokinetic enhancer that may increase exposure to concomitantly administered drugs that are substrates of cytochrome P450 (CYP) 3A4. Exposure to nifedipine, a substrate of CYP3A4, may increase due to ritonavir-mediated drug-drug interactions (DDIs). However, there are no real-world clinical data that quantify the magnitude of DDIs between nifedipine and ritonavir. Although a 50% reduction in nifedipine dosage is recommended when co-administration is unavoidable, the safety of this approach remains unclear. Here, we describe a prospective pharmacokinetic case report examining the interaction between nifedipine controlled-release (CR) and NMV-r in a 68-year-old woman treated with nifedipine CR and telmisartan. She was diagnosed with COVID-19 and initiated on NMV-r. Upon initiation of NMV-r therapy, the nifedipine CR dose was reduced by 50%. Despite this reduction, the patient's plasma trough concentrations of nifedipine increased approximately four-fold and seven-fold at 24 and 96 h after initiation, respectively, compared with baseline (22.4 vs. 93.3 vs. 157.6 ng/mL). Assuming a proportional relationship between the area under the concentration-time curve (AUC) and trough concentration, ritonavir increased the AUC of nifedipine by approximately 14-fold. Telmisartan was discontinued after reducing nifedipine due to hypotension. From a clinical perspective, temporary discontinuation of nifedipine-or prompt withdrawal in the event of symptomatic hypotension-may represent a safer management strategy for patients receiving ritonavir-containing therapy.

Для цитирования: Takase Tomoki, Kuroda Hirokazu, Fukushima Keizo, Oda Toshihiko, Masumoto Saki, Nadai Takanobu, Hotta Takumi, Fukushima Shoji, Kume Manabu, Hashida Tohru, Muroi Nobuyuki. Pharmacokinetic interaction between nirmatrelvir/ritonavir and nifedipine: A case report.. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2026. DOI: 10.1016/j.jiac.2026.102937.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.